Chemoradiotherapy For Anal Cancer: Clinical Trials Past, Present And Future
COLORECTAL CANCER(2014)
摘要
Anal cancer is a rare cancer whose incidence is increasing in the UK. It is associated with human papilloma virus infection and smoking and is more common in women and immunosuppressed individuals, including those with transplants and HIV infection. The current standard of care is chemoradiotherapy (CRT) to the pelvis with surgery reserved for patients where CRT is contraindicated or as salvage treatment for residual disease or recurrence post-CRT. Radiotherapy combined with mitomycin-C and 5-fluorouracil has emerged as the standard of care following a series of six well-conducted Phase III trials. Trials have shown no benefit for cisplatin-based combination regimens either concurrently, adjuvantly or neoadjuvantly.
更多查看译文
关键词
5FU, anal cancer, chemoradiotherapy, cisplatin, clinical trails, mitomycin
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要